Skip to content
Dose Brief
Menu

Evidence review

Is compounded semaglutide legit? What to check

A measured look at compounded semaglutide: what 503A and 503B pharmacies are, what LegitScript and FDA rules cover, and the checks that flag a safe provider.

By The Dose Brief Desk, News Editor
In this brief

The Desk's #1 pick

CoreAge Rx

94 · A

One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.

Visit CoreAge Rx
Semaglutide
$99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published
Tirzepatide
$149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published
Coverage
US only; restrictions by state, confirmed at intake
Access
Compounded

Advertising disclosure · we may earn a commission at no extra cost to you. It never changes a Brief Score — but it is why these two providers are the ones in this box.

Also here

Strut Health

84 · B

The cheapest oral semaglutide route in the ranking, priced per route rather than per dose — provided you stay on auto-refill.

FDA warning letter, February 2026 — issued to Strut Health, LLC dba Strut. See the FDA's warning letter database.

Visit Strut Health

'Is this legit?' is the right question to ask about compounded semaglutide, and the honest answer is: it can be, but it depends entirely on who's making it. Compounding is a legitimate, long-standing part of pharmacy — and it's also an area where quality varies more than with an FDA-approved product. Here's how to tell the difference without a pharmacy degree. The legal ground under it has also shifted: the shortage that made large-scale compounding permissible has ended for both molecules, which changes who may still compound them and on what terms. That status, with the dates, is in is compounded semaglutide still legal?.

What compounding actually is

A compounding pharmacy prepares a medication tailored to a prescription rather than dispensing a mass-manufactured product. Compounded drugs are legal, but they are not FDA-approved — the agency does not review each compounded formulation for safety, effectiveness, or quality the way it does an approved drug1. That single fact is why the pharmacy behind your medication matters so much: with a compounded product, its quality controls are doing the work the FDA approval process does for a brand.

503A vs 503B — the two kinds of compounder

Under federal law there are two categories. A 503A pharmacy compounds patient-specific prescriptions, typically at a traditional or telehealth-affiliated pharmacy scale. A 503B outsourcing facility registers with the FDA, is inspected on a risk-based schedule, and follows stricter manufacturing standards so it can produce larger batches1. Neither makes an FDA-approved product, but a 503B operates under more oversight. If a provider names a 503B partner, that's a meaningful signal; if it names its pharmacy at all and explains the setup, that's already better than most.

Where the shortage rules fit

Much of the compounded GLP-1 market grew during the period when brand-name semaglutide was on the FDA shortage list, which gave compounders more latitude to make copies2. As those shortages resolved, that latitude narrowed and regulatory attention increased. That doesn't make compounded semaglutide illegitimate — but it does mean the landscape is shifting, so a provider's compliance posture matters more than ever. The fuller story is in GLP-1 shortages and supply.

The checks that matter

Before you trust a compounded semaglutide provider, confirm a few things. Is it LegitScript-certified? LegitScript is an independent verification service, and its badge signals a provider has passed a compliance review — many of the providers we rate highly carry it. Does the provider name its 503A or 503B pharmacy partner, or at least explain its sourcing? For a sense of what a full answer looks like, Pallas Health names six dispensing pharmacies and publishes two prescribers' NPI numbers with a link to the federal registry to check them — the pharmacy list even explains the 503A/503B split rather than leaving you to work it out. That is unusual; most providers name nobody, and Oak is a plain example of what that looks like — its pages say only "Oak's contracted pharmacies" and "independent licensed physicians and nurse practitioners contracted through Oak's medical group partners", with no pharmacy, no clinician and no NPI published anywhere, while its own Terms, Privacy policy and checkout name three different operating companies between them. Is there a licensed clinician involved in prescribing, with a real health intake rather than a rubber-stamp form? Is your state served, and is licensing information available? And is the price stable and disclosed, or a teaser that hides the real cost? Our compounded semaglutide price and supply ranking shows which tracked providers currently pass that last test. A provider that answers those cleanly is playing it straight.

Red flags

Some signals should stop you. A provider that will not show you what it sells before you pay is near the top of the list: Lighter You publishes no product pages at all and gates its catalog behind a login, so the only way to learn what molecule, dose or format you are buying is to complete an intake — at which point you have already been charged. It is not a front, and it names four pharmacies with street addresses, which is more than most. But you cannot vet what you cannot read. No named pharmacy and no accreditation. Claims that a compounded product is 'FDA-approved' — it isn't, and saying so is a misrepresentation1. 'Research-only,' gray-market, or unusually additive-laden formulations — this is exactly the category retatrutide falls into, since it has no FDA-approved reference product at all and, unlike semaglutide, cannot legally be compounded under federal law by any pharmacy, licensed or not. No clinician contact. And prices so far below the market that you should ask how the provider can possibly source safely at that number. The same molecule still carries the FDA's boxed warning about thyroid C-cell tumors and its contraindications — see what that warning actually means — so a provider that skips real screening is cutting a corner that matters3. A provider that also skips real GI screening is the same corner behind the ongoing GLP-1 gastroparesis litigation, which is worth understanding regardless of which pharmacy you use.

The bottom line

Compounded semaglutide from a properly licensed, accredited pharmacy with real clinical oversight is a legitimate option that many people use. Compounded semaglutide from an anonymous website with a suspiciously low price is a gamble. The difference is entirely in the checks above — run them with our 5-minute provider checklist, understand how it compares to the brand in compounded vs brand-name GLP-1, and see which providers we score highest in our provider briefs. This is guidance for vetting a provider, not medical advice; your prescriber is the right person for decisions about your care.

Frequently asked questions

Is compounded semaglutide FDA-approved?

No. Compounded drugs are legal but not FDA-approved — the agency does not review each compounded formulation for safety, effectiveness, or quality. Any provider claiming its compounded semaglutide is FDA-approved is misrepresenting it.

What's the difference between a 503A and 503B pharmacy?

A 503A pharmacy compounds patient-specific prescriptions; a 503B outsourcing facility registers with the FDA, is inspected, and follows stricter manufacturing standards for larger batches. Neither makes an FDA-approved product, but a 503B operates under more oversight.

What should make me walk away from a provider?

No named pharmacy or accreditation, claims that the compounded product is FDA-approved, no clinician involvement or real health screening, 'research-only' framing, or prices so far below market that safe sourcing seems implausible.

References

  1. U.S. Food and Drug Administration (2024). Compounding and the FDA: Questions and Answers. FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  2. U.S. Food and Drug Administration (2025). FDA Drug Shortages database. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  3. U.S. Food and Drug Administration (2024). Wegovy (semaglutide) injection — Drugs@FDA prescribing information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.